KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Common Equity (2016 - 2026)

Medtronic's Common Equity history spans 12 years, with the latest figure at $48.9 billion for Q4 2025.

  • For Q4 2025, Common Equity changed 0.29% year-over-year to $48.9 billion; the TTM value through Oct 2025 reached $48.9 billion, changed 0.29%, while the annual FY2025 figure was $48.3 billion, 4.29% down from the prior year.
  • Common Equity for Q4 2025 was $48.9 billion at Medtronic, up from $48.1 billion in the prior quarter.
  • Across five years, Common Equity topped out at $52.8 billion in Q3 2022 and bottomed at $48.1 billion in Q3 2025.
  • The 5-year median for Common Equity is $51.6 billion (2021), against an average of $50.8 billion.
  • The largest annual shift saw Common Equity grew 3.66% in 2021 before it decreased 6.24% in 2024.
  • A 5-year view of Common Equity shows it stood at $52.2 billion in 2021, then fell by 0.2% to $52.1 billion in 2022, then dropped by 0.79% to $51.6 billion in 2023, then fell by 5.68% to $48.7 billion in 2024, then rose by 0.29% to $48.9 billion in 2025.
  • Per Business Quant, the three most recent readings for MDT's Common Equity are $48.9 billion (Q4 2025), $48.1 billion (Q3 2025), and $48.3 billion (Q2 2025).